XOMA 3AB

Drug Profile

XOMA 3AB

Alternative Names: XOMA-3AB

Latest Information Update: 26 Nov 2015

Price : $50

At a glance

  • Originator University of California at San Francisco; XOMA
  • Developer National Institute of Allergy and Infectious Diseases; XOMA
  • Class Antibacterials; Antitoxins; Monoclonal antibodies
  • Mechanism of Action Botulinum toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Botulism

Most Recent Events

  • 05 Nov 2015 Nanotherapeutics acquires biodefence antibodies, including XOMA 3AB from XOMA
  • 11 Mar 2015 XOMA has patent protection for anti-botulinum toxin antibodies in USA (XOMA form 10-K filed in March 2015)
  • 01 May 2013 National Institute of Allergy and Infectious Diseases completes a phase I trial for Botulism (in volunteers) in USA (NCT01357213)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top